Category | Feature |
---|---|
Antibody | IgG1 κ murine monoclonal antibody |
Stability of immunoconjugate | Stable urea-type bond |
Antibody used before therapeutic dose to enhance biodistribution | Rituximab (chimeric) |
Effective blood half-life | Mean, 27 h (range, 14–44 h) |
Urinary excretion | 7.3% ± 3.2% over 7 d |
Dosimetry | Not necessary for approved indication: 111In-ibritumomab tiuxetan used as surrogate in imaging performed to confirm expected biodistribution as additional safety measure |
Administration | Outpatient |
Treatment duration | 8 d |
Development of human antimouse or human antichimeric antibodies | 1%–2% of patients |
Features are from Wiseman et al. (6) and Zelenetz (7).